Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

South Korean CrystalGenomics Targets U.S. And Europe For Osteoarthritis Product

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's CrystalGenomics plans to conduct a Phase IIb or Phase III osteoarthritis safety and efficacy study for its next-generation NSAID CG100649, possibly in Asia next year following positive results from its Phase IIa clinical study in 25 European clinical centers in Germany, Hungary and Ukraine

You may also be interested in...



Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate

SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe

Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate

SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe

Bausch & Lomb Collaborates With Galapagos On Ophthalmic Disease Candidates

Eye health company joins long list of pharmaceutical firms partnering with Galapagos in past year.

Table

View full table

Tags:
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

SC067494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By